Abstract: Objective The aim of this study was to investigate ultrasound-guided polidocanol sclerotherapy in patients with hepatic cysts (HC). Methods Ninety-one patients with HC were recruited in Henan Provincial Children's Hospital between March 2022 and March 2024, and were randomly divided into control group (n=45) and observation group (n=46), receiving ethanol sclerotherapy, or polidocanol sclerotherapy under ultrasound-guidance. Serum Golgi protein 73 (GP73), protein disulfide isomerase A3 (PDIA3) and chitinase 3-like protein 1 (CHI3L1) levels were detected by using automatic immunoassay analyzer, and serum superoxide dismutase (SOD), nuclear factor E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) levels were measured by ELISA. Results After treatment, serum ALT and AST levels in the observation group were 48.4±9.2U/L and 38.4±7.3U/L, both significantly lower than [59.8±11.3U/L and 62.0±14.3U/L, P<0.05] in the control; serum GP73, PDIA3 and CHI3L1 levels were 24.4±3.6pg/L, 67.7±5.2ng/mL and 46.4±5.8ng/L, all much lower than [36.4±5.1pg/L, 92.7±5.4ng/mL and 65.8±6.4ng/L, respectively, P<0.05] in the control group; serum SOD, Nrf2 and HO-1 levels were 83.5±8.3 U/L, 713.3±82.3 U/L and 27.7±3.1U/L, all much higher than [77.5±7.8U/L, 664.7±75.3U/L and 23.7±2.5U/L, respectively, P<0.05] in the control; post-operationally, incidence of adverse effects in the observation group was 6.5%, much lower than 24.4%(P<0.05)in the control; six months after sclerotherapy, disappearance rate of HC in the observation group was 87.0%, much higher than 66.7%(P<0.05)in the control group. Conclusion Our observation backs up lauromacrogol sclerotherapy under ultrasound-guidance in patients with HC, which is efficacious and safe.

Key words: Hepatic cysts, Ultrasound-guidance, Polidocanol, Ethanol, Therapy